NERV (Minerva Neurosciences) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


NERV Minerva Neurosciences Inc NERV
32 GF Score
Price $4.32
! 1 Warning Sign
View Full Analysis

What is Minerva Neurosciences Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Minerva Neurosciences's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

NERV vs YDES, CAMP, IKT: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Minerva Neurosciences's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minerva Neurosciences Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Margin of Safety % (DCF Earnings Based) falls into.


NERV
32GF Score
Minerva Neurosciences Inc NERV
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minerva Neurosciences Business Description

Other Exchanges 4MNA:Germany
Address 1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
32GF Score

Get the complete analysis for NERV

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.32
Price